Measuring Hope and Hopelessness in Cancer
This study has been completed.
Sponsor:
Memorial Sloan-Kettering Cancer Center
Collaborators:
Fordham University
Calvary Hospital, Bronx, NY
Peter MacCallum Cancer Centre, Australia
Information provided by:
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00581880
First received: December 21, 2007
Last updated: January 14, 2009
Last verified: January 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to develop an accurate and useful way of measuring patients' thoughts and feelings about hope and hopelessness as they relate to their illness. Doctors and psychologists from Memorial Sloan-Kettering Cancer Center, Calvary Hospital, the Peter MacCallum Cancer Centre, and Fordham University are working together to design a new measure. Findings from this research will help us study the nature of illness and develop improved methods of diagnosis and treatment. We hope what we learn from you will help us learn more about how to care better for patients with cancer and other severe illnesses.
| Condition | Intervention |
|---|---|
|
Advanced Cancer |
Behavioral: questionnaires |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Measuring Hope and Hopelessness in Cancer |
Resource links provided by NLM:
Further study details as provided by Memorial Sloan-Kettering Cancer Center:
Primary Outcome Measures:
- To explore and better understand the construct of hopelessness as it applies to terminally ill cancer patients. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
- To develop a brief self-report measure of hopelessness grounded in the construct of hopelessness as it applies to terminally ill cancer patients. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To establish the reliability and validity of this newly developed measure of hopelessness in a large sample of terminally ill cancer patients. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
| Enrollment: | 288 |
| Study Start Date: | January 2005 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Terminally Ill patients
|
Behavioral: questionnaires
A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Subjects will be recruited in equal numbers from Memorial Hospital and Calvary Hospital or Peter MacCallum Cancer Centre at each stage of data collection.
Criteria
Inclusion Criteria:
- 18 years of age or older.
- Patients who are able to understand verbal and written English.
- Diagnosis of cancer.
- Patients with advanced cancer receiving ambulatory or inpatient care at Memorial Sloan-Kettering Cancer Center in New York City. Patients at Calvary Hospital and Peter MacCallum Cancer Centre admitted for palliative care will also be eligible for participation in this study
Exclusion Criteria:
- The presence of a psychotic mental disorder (e.g., Bipolar Disorder, Schizophrenia, Schizo-affective illness, psychosis due to substance abuse) as indicated in medical chart.
- Cognitive impairment so severe (i.e., Mini-Mental State exam score of less than 20) that, in the opinion of the Principal Investigator or Project Coordinator, would interfere with a patient's ability to give informed consent for research.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00581880
Locations
| United States, New York | |
| Memorial Sloan Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Fordham University
Calvary Hospital, Bronx, NY
Peter MacCallum Cancer Centre, Australia
Investigators
| Principal Investigator: | William Breitbart, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | William Breitbart, MD, Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00581880 History of Changes |
| Other Study ID Numbers: | 04-145 |
| Study First Received: | December 21, 2007 |
| Last Updated: | January 14, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
|
end stage Terminally Ill |
Additional relevant MeSH terms:
|
Neoplasms |
ClinicalTrials.gov processed this record on May 23, 2013